Andra AP fonden Sells 260,199 Shares of Gilead Sciences, Inc. $GILD

Andra AP fonden trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 53.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 222,601 shares of the biopharmaceutical company’s stock after selling 260,199 shares during the period. Andra AP fonden’s holdings in Gilead Sciences were worth $31,024,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in the stock. Wilkerson Advisory Group LLC raised its stake in Gilead Sciences by 54.2% in the first quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 78 shares in the last quarter. Glenview Trust Co lifted its holdings in shares of Gilead Sciences by 1.4% during the 1st quarter. Glenview Trust Co now owns 192,157 shares of the biopharmaceutical company’s stock worth $26,781,000 after acquiring an additional 2,683 shares during the period. Long Road Investment Counsel LLC lifted its holdings in shares of Gilead Sciences by 4.2% during the 1st quarter. Long Road Investment Counsel LLC now owns 24,950 shares of the biopharmaceutical company’s stock worth $3,477,000 after acquiring an additional 1,000 shares during the period. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Gilead Sciences during the 1st quarter worth approximately $111,000. Finally, Meeder Advisory Services Inc. boosted its position in shares of Gilead Sciences by 5.1% during the 1st quarter. Meeder Advisory Services Inc. now owns 35,812 shares of the biopharmaceutical company’s stock worth $4,991,000 after acquiring an additional 1,722 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Morgan Stanley lowered their price objective on shares of Gilead Sciences from $168.00 to $166.00 and set an “overweight” rating for the company in a research report on Wednesday, July 8th. Rothschild & Co Redburn reduced their target price on Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. Leerink Partners lowered their price target on Gilead Sciences from $148.00 to $146.00 in a report on Friday, May 8th. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 price objective on shares of Gilead Sciences in a research report on Monday, July 6th. Finally, The Goldman Sachs Group raised their price objective on Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research note on Friday, April 17th. Twenty-six analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $159.04.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the sale, the chief financial officer directly owned 171,646 shares in the company, valued at $21,524,408.40. This trade represents a 1.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the sale, the insider directly owned 125,779 shares in the company, valued at $16,513,524.91. The trade was a 18.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 77,000 shares of company stock worth $9,978,740 in the last quarter. 0.30% of the stock is owned by insiders.

Gilead Sciences Trading Down 0.8%

Shares of GILD stock opened at $133.21 on Tuesday. Gilead Sciences, Inc. has a twelve month low of $107.75 and a twelve month high of $157.29. The stock’s fifty day simple moving average is $129.72 and its 200 day simple moving average is $135.37. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The firm has a market capitalization of $165.39 billion, a P/E ratio of 18.15 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same period last year, the company earned $1.81 earnings per share. The business’s quarterly revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post -0.77 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were issued a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date was Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.